Streetbeat News

CDT

Conduit Pharmaceuticals Inc.

https://www.conduitpharma.com

Industry

Biotechnology

Conduit Pharmaceuticals Inc. operates as a clinical stage specialty biopharmaceutical company that provides unmet medical needs in the areas of autoimmune disease and idiopathic male infertility. It's pipeline includes AZD1656 for the treatment of hashimoto's thyroiditis, renal transplant, uveitis, and preterm labor; and AZD5904 for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Open

0.14

Mkt cap

11M

Volume

575M

High

0.16

P/E Ratio

-0.47

52-wk high

7.83

Low

0.10

Div yield

N/A

52-wk low

0.08

AstraZeneca has reported a 9.9% passive stake in Conduit Pharmaceuticals, indicating a strategic interest in the company. This move could suggest potential future collaborations or investments.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 12:03 pm

In Thursday's pre-market session, several healthcare stocks experienced significant price movements. Theriva Biologics, Conduit Pharmaceuticals, and ENDRA Life Sciences were among the top gainers, while Windtree Therapeutics, Soligenix, and Kazia Therapeutics saw notable declines.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 12:06 pm

Levi Strauss shares dropped over 10% in pre-market trading after reporting better-than-expected earnings but missing sales estimates for Q3. The company provided a fiscal year 2024 earnings forecast slightly below analyst expectations. Several other stocks experienced significant pre-market movements.

Portfolio Pulse from Avi Kapoor

October 03, 2024 | 9:24 am

The article reports on the after-market session movements of various healthcare stocks. Notable gainers include Carmell (CTCX) with a 31% increase and Processa Pharma (PCSA) with a 30.07% rise. Among the losers, Soligenix (SNGX) saw an 8.6% decline, and Inspire Veterinary (IVP) fell by 6.34%.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 8:31 pm

Zhibao Technology shares surged 18.8% in pre-market trading after winning a tender to provide services to the People’s Insurance Company of China. Other notable pre-market movers include Sify Technologies, Aptose Biosciences, and United States Steel Corporation.

Portfolio Pulse from Avi Kapoor

September 03, 2024 | 9:13 am

In Monday's after-market session, several health care stocks experienced significant price movements. Conduit Pharmaceuticals, TNF Pharmaceuticals, and Holdco Nuvo Group DG were among the top gainers, while Renalytix, Bluejay Diagnostics, and IO Biotech saw notable declines.

Portfolio Pulse from Benzinga Insights

September 02, 2024 | 8:31 pm

Serve Robotics Inc. (NASDAQ:SERV) shares rose 14% in pre-market trading after reporting better-than-expected second-quarter sales. Other notable pre-market movers include Digital Ally, Inc. (NASDAQ:DGLY) up 80.7% after a patent grant, and Ouster, Inc. (NYSE:OUST) down 16.9% after weak sales results and guidance.

Portfolio Pulse from Avi Kapoor

August 14, 2024 | 9:35 am

Conduit Pharmaceuticals has selected initial indications for its lead clinical candidate, HK-4 Glucokinase Activator AZD1656, licensed from AstraZeneca. Conduit plans to initiate Phase 2a clinical trials to evaluate AZD1656 for the treatment of systemic lupus erythematosus and ANCA-associated vasculitis. Originally developed by AstraZeneca for diabetes mellitus, AZD1656 has undergone extensive safety testing. Conduit aims to leverage its safety profile and targeted mechanism to address autoimmune disorders.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:27 am

Conduit Pharmaceuticals shares are trading higher after the company announced it entered into an exclusive license agreement with AstraZeneca to develop AZD1656 and AZD5658.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:38 am

Conduit Pharmaceuticals (NASDAQ: CDT) has entered into a licensing agreement with AstraZeneca (NASDAQ: AZN) to develop and commercialize three drug candidates. AstraZeneca will receive Conduit shares and a share of sublicense revenues. Conduit plans to conduct Phase 2 trials in 2024.

Portfolio Pulse from Vandana Singh

August 08, 2024 | 10:00 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.